EVGN Evogene Ltd.

Nasdaq evogene.com


$ 1.21 $ 0.00 (0 %)    

Thursday, 06-Nov-2025 07:39:10 EST
QQQ $ 624.75 $ 0.00 (0 %)
DIA $ 473.54 $ 0.00 (0 %)
SPY $ 679.00 $ 0.00 (0 %)
TLT $ 89.37 $ 0.00 (0 %)
GLD $ 369.18 $ 0.00 (0 %)
$ 1.18
$ 1.21
$ 1.18 x 2,100
$ 1.21 x 149
-- - --
$ 0.95 - $ 2.42
86,656
na
7.69M
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 preview-evogenes-earnings
Preview: Evogene's Earnings
08/18/2025 15:02:56

 lake-street-maintains-buy-on-evogene-lowers-price-target-to-35

Lake Street analyst Ben Klieve maintains Evogene (NASDAQ:EVGN) with a Buy and lowers the price target from $5 to $3.5.

 evogene-q1-eps-038-beats-063-estimate-sales-244m-miss-442m-estimate

Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.63) by 39...

 icl-to-acquire-majority-activity-of-evogenes-subsidiary-lavie-bio-term-not-disclosed

Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological productsREHOVOT, Israel, ...

 evogene-q4-2024-gaap-eps-006-may-not-be-comparable-to-072-estimate-sales-161m-miss-363m-estimate

Evogene (NASDAQ:EVGN) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.72) by 10...

 evogene-q3-2024-gaap-eps-131-misses-063-estimate-sales-180m-miss-285m-estimate

Evogene (NASDAQ:EVGN) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.63) by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION